3-((2S,5S)-5-Methyl-3,6-dioxopiperazin-2-yl)propanamide

Catalog No. :
ACKUGE348
CAS No. :
268221-76-7
Molecular Formula :
C8H13N3O3
Molecular Weight :
199.21

IUPAC Name:3-((2S,5S)-5-Methyl-3,6-dioxopiperazin-2-yl)propanamide

3-((2S,5S)-5-Methyl-3,6-dioxopiperazin-2-yl)propanamide structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg97%$109.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name3-((2S,5S)-5-Methyl-3,6-dioxopiperazin-2-yl)propanamide
IUPAC Name3-((2S,5S)-5-Methyl-3,6-dioxopiperazin-2-yl)propanamide
MDL No.MFCD05663453
Molecular FormulaC8H13N3O3
Molecular Weight199.21
SMILESO=C(N)CC[C@@H](C(N[C@H]1C)=O)NC1=O
InChI KeyPNSKRAHOHQWAAN-WHFBIAKZSA-N
SynonymCYCLO(-ALA-GLN);Cyclo(-Ala-Gln) ,98%;Cyclo(L-Ala-L-Gln);3-((2S,5S)-5-methyl-3,6-dioxopiperazin-2-yl)propanamide;Alanyl Glutamine Impurity Ⅰ:Cyclo(L-Ala-L-Gln);L-Alanyl-L-Glutamine impurity 22;circle -(L- alanyl -L- glutamine);Ring-(L-alanyl-L glutamine)
CAS No.268221-76-7

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACKUGE348 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACAYOL972 route compound structure diagram
    ACAYOL97210060-13-6 In Stock
  4. Then
  5. ACKUGE348 route product structure diagram
    ACKUGE348268221-76-7
Inquiry

2. ACKUGE348 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACAYOL972 route compound structure diagram
    ACAYOL97210060-13-6 In Stock
  4. Then
  5. ACKUGE348 route product structure diagram
    ACKUGE348268221-76-7
Inquiry

Comments (0)